Article ; Online: Extended-release ranolazine: critical evaluation of its use in stable angina.
Vascular health and risk management
2011 Volume 7, Page(s) 535–539
Abstract: Coronary heart disease is the major cause of morbidity and mortality throughout the world, and is responsible for approximately one of every six deaths in the US. Angina pectoris is a clinical syndrome characterized by discomfort, typically in the chest, ...
| Abstract | Coronary heart disease is the major cause of morbidity and mortality throughout the world, and is responsible for approximately one of every six deaths in the US. Angina pectoris is a clinical syndrome characterized by discomfort, typically in the chest, neck, chin, or left arm, induced by physical exertion, emotional stress, or cold, and relieved by rest or nitroglycerin. The main goals of treatment of stable angina pectoris are to improve quality of life by reducing the severity and/or frequency of symptoms, to increase functional capacity, and to improve prognosis. Ranolazine is a recently developed antianginal with unique methods of action. In this paper, we review the pharmacology of ranolazine, clinical trials supporting its approval for clinical use, and studies of its quality of life benefits. We conclude that ranolazine has been shown to be a reasonable and safe option for patients who have refractory ischemic symptoms despite the use of standard medications (for example, nitrates, beta-adrenergic receptor antagonists, and calcium channel antagonists) for treatment of anginal symptoms, and also provides a modestly improved quality of life. |
|---|---|
| MeSH term(s) | Acetanilides/adverse effects ; Acetanilides/therapeutic use ; Angina, Stable/diagnosis ; Angina, Stable/drug therapy ; Angina, Stable/physiopathology ; Angina, Stable/psychology ; Animals ; Cardiovascular Agents/adverse effects ; Cardiovascular Agents/therapeutic use ; Delayed-Action Preparations ; Humans ; Piperazines/adverse effects ; Piperazines/therapeutic use ; Quality of Life ; Ranolazine ; Treatment Outcome |
| Chemical Substances | Acetanilides ; Cardiovascular Agents ; Delayed-Action Preparations ; Piperazines ; Ranolazine (A6IEZ5M406) |
| Language | English |
| Publishing date | 2011-08-25 |
| Publishing country | New Zealand |
| Document type | Journal Article ; Review |
| ZDB-ID | 2186568-1 |
| ISSN | 1178-2048 ; 1176-6344 |
| ISSN (online) | 1178-2048 |
| ISSN | 1176-6344 |
| DOI | 10.2147/VHRM.S15560 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6066: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.